Vernstrom L, et al. - In this study, experts sought to examine whether platelet aggregation increased during the standard 24-hour aspirin dosing interval in patients with type 2 diabetes (T2DM) compared to non-diabetic controls and to assess baseline platelet aggregation, the acute effects of aspirin on platelet aggregation and platelet turnover. At the end of the standard 24-hour dosing interval of aspirin, patients with T2DM without a history of cardiovascular disease (CVD) and controls had increased platelet aggregation. Moreover, compared to controls, aspirin-naïve T2DM patients had increased platelet aggregation.